The basis of a more contagious 501Y.V1 variant of SARS-CoV-2
Open accessPublished version of a preprint
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Dear Editor, The SARS-CoV-2 virus has infected over one hundred million people (COVID-19 patients) and caused more than two million deaths to date. The number of infected people continues to grow quickly, emphasizing the need for rapid use of effective vaccines. Although two mRNA vaccines based on Spike protein (produced by Pfizer-BioNTech and MODERNA) have been approved for emergency use in the US, the increasing Spike variants that have appeared around the world raise concerns about the continued efficacy of the vaccines. Monoclonal antibodies, developed by Regeneron and Eli Lilly, specifically targeting the native form of Spike have been approved by the FDA for emergency use. An N501Y variant (Y501) of the Spike protein of SARS-CoV-2 (B.1.1.7, 20I/501Y.V1), first emerged in UK and has now spread to the rest of the world. This variant appears to be much more contagious than the original N501 version. Furthermore, Y501 mutation is also found in a variant (B.1.351, 20H/501Y. V2) from South Africa and a variant (P1, 20J/501Y.V3) from Brazil. Unfortunately, this mutation is located at the interaction surface between the RBD and human Angiotensin Converting Enzyme 2 (ACE2). Thus, the Y501 variation present in B.1.1.7, 20I/501Y.V1 might affect the binding ability of the RBD to bind ACE2. We therefore compared the binding affinity of N501 and Y501 RBD for ACE2, uncovering that the affinity for ACE2 of the Y501-RBD was ~10 fold higher than that of the N501 version. This may account, at least in part, for the greater infectivity of SARS-CoV-2 with this mutation. Structural modeling data showed that Y501-RBD can form an additional aromatic ring–ring interaction and an additional hydrogen bond with ACE2 by comparison with the RBD of the wild type. In spite of this, sera from individuals immunized with the Pfizer-BioNTech vaccine still efficiently block ACE2 binding to Y501-RBD. Furthermore, Bamlanivimab, the recently FDA approved therapeutic antibody drug for treatment of COVID-19 patients still binds the variant Y501-RBD as efficiently as it binds the N501-RBD, giving hope that treatment with the existing monoclonal antibodies may still help COVID-19 patients. To investigate the basis for the more highly infectious property of the N501Y variant, we expressed two versions of SARS-CoV-2 RBD, N501-RBD and Y501-RBD (residues 319–541 aa) in 293F cells (Supplementary information, Fig. S1). Purified proteins of both types were subjected to Surface Plasmon Resonance (SPR) binding assays on a Biacore machine to examine their binding affinities for ACE2. The binding affinity between the native form of RBD (N501RBD) and ACE2 was ~5.76 nM (Fig. 1a), similar to the ~4.5 nM previously reported. To our surprise, the binding affinity of the mutated version of the RBD, Y501-RBD, increased dramatically to ~0.566 nM (Fig. 1b). It has been reported that the affinity of the RBD of SARS-CoV-2 for ACE2 is ~7 fold higher than that of the RBD of SARS-CoV for the same ligand, ACE2. The ~7 fold increase in binding affinity could be one major reason that allowed SARSCoV-2 to be more infectious than SARS-CoV. By extension of this argument, the current mutation of N501 to Y501, and consequently its ~10 times greater affinity for ACE2, may account for the increased infection rate by this variant in UK. Likewise, it may also account for the increased transmission rate of both the South African (20H/501Y.V2) and Brazil variants (20J/501Y.V3), although their additional K417N/T and E484K mutations besides N501Y may also contribute. A 2.9 Å resolution Cryo-EM structure of a predicted potential variant containing numerous mutations including E484K, Q498R, N501Y bound to ACE2 has been published. It shows a detailed interaction of the side chain of Y501 of the RBD and Y41 of ACE2. However, the introduction of Q498R, a mutation that does not exist in current variants, might affect the properties of the Y501 interaction with ACE2 since Q498R is quite close to the 501 position. Thus the reported structure could not unequivocally attribute the ~10 fold increase in affinity of the variant RBD vs N501-RBD for ACE2 to the Y501 change. Here, we used modern molecular modeling programs to make a prediction about the relevant binding sites. Based on the reported structure of the N501-RBD and ACE2, we generated a Y501-RBD–ACE2 complex in the program COOT and used the docking program HADDock 2.2 server to carry out optimization (Fig. 1c, d; Supplementary Information). In the case of the wild type SARS-CoV-2 Spike, the side chain of N501 within N501-RBD forms a hydrogen bond with Y41 of ACE2 (Fig. 1c). This interaction is markedly changed in the interaction between the Y501-RBD mutant and ACE2 (Fig. 1d). Although the hydrogen bond between N501-RBD and Y41 of ACE2 disappears for the Y501-RBD mutant, two new forms of interactions, are predicted to exist between Y501-RBD and ACE2 (Fig. 1d). First, the Y501 of Y501-RBD forms two new hydrogen bonds with the side chains of D38 and K353 of ACE2 (Fig. 1d). Second, the aromatic ring of Y501 also has a strong aromatic stacking interaction (π stacking) with the aromatic ring of Y41 of ACE2 (Fig. 1d). It is quite likely that the ring–ring interaction contributes to the much higher binding affinity between Y501RBD and ACE2. Nevertheless, these detailed interactions still need confirmation with a high-resolution structure of Y501-RBD–ACE2 complex. It has been reported that ~90% of broadly neutralizing antibodies from COVID-19 patients target the RBD. Thus, it is important to test if the binding of these broadly neutralizing antibodies is affected by the change of N501-RBD to Y501-RBD. To this end, we tested sera from individuals immunized with the mRNA vaccine from Pfizer-BioNTech. An N501-RBD specific ELISA detected high titers of IgG antibodies in five immunized individuals (Supplementary information, Fig. S2), suggesting that the vaccine triggered strong immune responses in these individuals. To test the blocking property of broadly neutralizing antibodies toward both native and mutated RBDs, each type of RBD was immobilized on a separate channel of the same Biacore Chip at equal amount. Equal amounts of serum from one vaccinated individual were injected into the two channels. The results showed that both RBDs retained the same amount of antibodies at the different dilutions of injected antibodies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Self-citationGrifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
Baum, A., Ajithdoss, D., Copin, R., Zhou, A., Lanza, K., Negron, N., Ni, M., Wei, Y., Mohammadi, K., Musser, B., et al. (2020) · Science · doi:10.1126/science.abe2402 · Cited by 517
Research works printed but not linked: 5
- Tegally, H. et al. medRxiv https://doi.org/10.1101/2020.12.21.20248640 (2020). · DOI · Paper page
- Zahradnik, et al. bioRxiv https://doi.org/10.1101/2021.01.06.425392 (2021). · DOI · Paper page
- Piccoli, L. et al. Cell 183, 1024–1042 (2020). · DOI · Paper page
- Jones, B. E. bioRxiv https://doi.org/10.1101/2020.09.30.318972 (2020). · DOI
- Liu, H. bioRxiv https://doi.org/10.1101/2021.02.16.431305 (2021). · DOI
Cited by
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Markov, P. V., Ghafari, M., Beer, M., Lythgoe, K., Simmonds, P., Stilianakis, N. I., & Katzourakis, A. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00878-2 · Cited by 1,179
Neutralizing monoclonal antibodies for treatment of COVID-19
Taylor, P. C., Adams, A. C., Hufford, M. M., de la Torre, I., Winthrop, K., & Gottlieb, R. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00542-x · Cited by 732
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K. S., Marquez, A. C., Sekirov, I., & Subramaniam, S. (2022) · Science · doi:10.1126/science.abn7760 · Cited by 630
Metadata
- Authors
- Liu, H., Zhang, Q., Wei, P., Chen, Z., Aviszus, K., Yang, J., Downing, W., Jiang, C., Liang, B., Reynoso, L., Downey, G. P., Frankel, S. K., Kappler, J., Marrack, P., & Zhang, G.
- Venue
- Cell Research
- Published
- 2021-04-23
- Volume
- 31
- Issue
- 6
- Pages
- 720-722
- ISSN
- 1001-0602 (ISSN-L)
- 1748-7838
- OpenAlex
- W3153049682
- Cited by
- 156
- References
- 9
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM135421)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. https://app.cochat.ai/papers/10.1038/s41422-021-00496-8
- The paper
- Liu, H., Zhang, Q., Wei, P., Chen, Z., Aviszus, K., Yang, J., Downing, W., Jiang, C., Liang, B., Reynoso, L., Downey, G. P., Frankel, S. K., Kappler, J., Marrack, P., & Zhang, G. (2021). The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. Cell Research. https://doi.org/10.1038/s41422-021-00496-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.